IRIS
POGGIO, FRANCESCA BENEDETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.713
Totale 2.713
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 2.713
Totale 2.713
Salva come PNG Salva come JPEG
Città #
Genova 1.877
Rapallo 414
Genoa 372
Vado Ligure 28
Bordighera 22
Totale 2.713
Salva come PNG Salva come JPEG
Nome #
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 132
Management of young women with early breast cancer 114
Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: A systematic review and meta-analysis of individual patient–level data 113
Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients 111
New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients 110
Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: Results of an observational study 110
News on the medical treatment of young women with early-stage HER2-negative breast cancer 109
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials 108
Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial 107
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis 106
The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients 105
The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients 99
Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects 97
Patterns of care and clinical outcomes of first-line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients relapsing after (Neo)adjuvant trastuzumab: An Italian multicenter retrospective cohort study 96
Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines 92
Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of Fc gamma RIIIA/Fc gamma RIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines 91
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review 90
Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis 89
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study 87
Role of dose-dense chemotherapy in high-risk early breast cancer 86
Controversies in Oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do? 81
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: exploratory analysis of the GIM2 trial 78
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study 71
Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis 68
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial 63
Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival A Randomized Clinical Trial 61
Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak 53
Protecting Ovaries During Chemotherapy Through Gonad Suppression: A Systematic Review and Meta-analysis 52
Fertility counseling of young breast cancer patients 48
Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study 48
Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: a systematic review and meta-analysis 34
null 27
Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial 26
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial 25
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) 20
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies 15
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial 13
Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’: (ESMO Open (2021) 6(2), (S2059702921000089), (10.1016/j.esmoop.2021.100054)) 9
SNPs of aromatase predict long-term survival and aromatase inhibitor toxicity in patients with early breast cancer: a biomarker analysis of the GIM4 and GIM5 trials 6
Patterns of care at the end of life: a retrospective study of Italian patients with advanced breast cancer 3
"Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper" 2
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial 1
Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER study 1
Totale 2.857
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.822
article - articoli 10.822
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.644
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020933 0 21 16 52 96 144 161 106 101 133 75 28
2020/2021366 24 45 35 30 20 39 16 40 18 47 19 33
2021/2022416 16 17 26 52 15 45 10 88 42 42 12 51
2022/2023492 48 53 6 55 73 75 11 40 68 2 59 2
2023/2024294 11 29 4 51 23 22 23 21 15 19 23 53
2024/202565 47 18 0 0 0 0 0 0 0 0 0 0
Totale 2.857